Ann: ELX LEAD Clinical trial results, page-44

I'd like to take the credit, but I didn't find the FDA changes, it was Imback.

Personally I'm erring on the side of caution and not factoring in US FDA 2RT approval for AMD. Given 2RT is already FDA approved for CSME maybe some ophthalmologists in the US will be convinced by the data and start to use, but I'd say it will be a hard slog to convince most until new trial results, or years of good results by the early adopters. Years of biotech investing I have found the medical community very slow to change ie cautious without clear cut trial results. A why stick your neck out mentality.

Still I was never here for 2RT, so happy to continue to hold. At 4% portfolio weighting and free carried I can afford the risk/ reward situation. Family history of glaucoma too keeps me interested in iTrack.